Please login to the form below

Not currently logged in
Email:
Password:

Immuno-oncology's evolution: impacts for pharma market researchers
Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.

Over the past 12 months several new products have been approved for a wider range of tumour types and with pipelines boasting numerous other products in the area, competition looks set to hot up.

On November 17 Research Partnership, in association with PMGroup, will host a free webinar which will explore the key features of the immuno-oncology market and the critical success factors for remaining competitive.

Key areas that will be discussed include: 

Setting the context
The current situation in immuno-oncology and challenges and opportunities for new targeted therapies entering the market.

Portfolio Panning
Understanding where to invest in the early stages of new product development in order to achieve your objectives.

Marketing and communications
Considerations for the positioning and marketing communications strategy with regards to the evolution of each indication. How this will impact your market research needs.

Biomarker strategies
The impact of biomarker availability on patient selection and sequencing. How to ensure your biomarker strategies are optimised for your brand.

If you have any further comments or questions regarding today’s webinar or would like to know more about our experience in immuno-oncology research, please visit www.researchpartnership.com

 

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics